Почетна › Многи мијелом › Северна Каролина › Durham
Kliničke studije za Многи мијелом u gradu Durham, NC
36 studija za Многи мијелом traži učesnike na lokacijama u gradu Durham i okolini (u krugu od oko 30 milja). Otvorite studiju da biste videli ko može da učestvuje i kako kontaktirati tim studije.
Zvanični tekst studije (na engleskom)
Tražite učesnike za studiju? Istaknite je na vrhu ove stranice — $99 za 30 dana →
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
Тражи се учесникФаза 1
- University of North Carolina /ID# 251203, Chapel Hill · 10 ми удаљено
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Тражи се учесникФаза 1
- University of North Carolina at Chapel Hill, Chapel Hill · 10 ми удаљено
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Тражи се учесникФаза 3
- Durham VAMC, Durham
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Тражи се учесникФаза 3
- Durham VAMC, Durham
- University of North Carolina, Chapel Hill · 10 ми удаљено
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
Тражи се учесникФаза 1
- University of North Carolina Hospitals at Hillsborough, Chapel Hill · 10 ми удаљено
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Тражи се учесникФаза 2
- UNC Hospitals Adult Oncology Clinics, Chapel Hill · 10 ми удаљено
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
Тражи се учесникФаза 1
- Duke Cancer Center, Durham
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Тражи се учесникОпсервациона студија
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10 ми удаљено
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Тражи се учесникФаза 1/2
- University Of North Carolina Health Care - Hillsborough Campus /ID# 272454, Hillsborough · 13 ми удаљено
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Тражи се учесникФаза 1
- Duke University Hospital, Durham
A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
Тражи се учесникФаза 3
- Research Site, Durham
- Research Site, Chapel Hill · 10 ми удаљено
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
Тражи се учесникФаза 1/2
- University of North Carolina at Chapel Hill /ID# 274667, Chapel Hill · 10 ми удаљено
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Тражи се учесникФаза 2/3
- University of North Carolina at Chapel Hill /ID# 277708, Chapel Hill · 10 ми удаљено
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Тражи се учесникФаза 3
- Duke University, Durham
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Тражи се учесникФаза 1/2
- Research Site, Durham
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Тражи се учесникФаза 2
- University of North Carolina Medical Center, Chapel Hill · 10 ми удаљено
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Тражи се учесникФаза 3
- Research Site, Chapel Hill · 10 ми удаљено
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Тражи се учесникФаза 3
- Duke University Medical Center, Durham
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
Тражи се учесникФаза 2
- Duke University Medical Center, Durham
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Тражи се учесникФаза 2
- Lineberger Comprehensive Cancer Center, Chapel Hill · 10 ми удаљено
HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM
Тражи се учесникФаза 2
- Duke University Health System, Durham
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
Тражи се учесникФаза 1
- University of North Carolina Hospitals at Hillsborough, Hillsborough · 13 ми удаљено
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
Тражи се учесникФаза 1/2
- GSK Investigational Site, Chapel Hill · 10 ми удаљено
DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics
Тражи се учесник
- Lineberger Comphrehensive Cancer Center at University of North Carolina, Chapel Hill · 10 ми удаљено
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Тражи се учесникФаза 3
- Research Site, Durham
- Research Site, Chapel Hill · 10 ми удаљено
Selinexor and Backbone Treatments of Multiple Myeloma Patients
Тражи се учесникФаза 1/2
- Duke Institute of Cancer/ Duke University, Durham
A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
Тражи се учесникФаза 2
- University of North Carolina (Data Collection Only), Chapel Hill · 10 ми удаљено
Registry of Older Patients With Cancer
Тражи се учесникОпсервациона студија
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10 ми удаљено
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
Тражи се учесникФаза 2
- University of North Carolina, Chapel Hill · 10 ми удаљено
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
Тражи се учесникФаза 2
- Duke Comprehensive Cancer Center, Durham
- University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill · 10 ми удаљено
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
Тражи се учесникФаза 1
- University Of North Carolina Health Care - Hillsborough Campus /ID# 278230, Hillsborough · 13 ми удаљено
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Тражи се учесникФаза 1
- University of North Carolina, Chapel Hill · 10 ми удаљено
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
Тражи се учесникФаза 1
- University of North Carolina, Chapel Hill · 10 ми удаљено
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Тражи се учесникФаза 1/2
- Duke University, Durham
- UNC Hospital, Chapel Hill · 10 ми удаљено
Registry for Adults With Plasma Cell Disorders (PCD's)
Тражи се учесникОпсервациона студија
- North Carolina Cancer Hospital, Chapel Hill · 10 ми удаљено
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Тражи се учесникФаза 1
- Duke University Health System (DUHS), Durham
Studije za Многи мијелом u drugim gradovima
- New York City, NY59 студија
- Boston, MA45 студија
- Atlanta, GA42 студија
- Houston, TX39 студија
- Nashville, TN31 студија
- Denver, CO26 студија
- St. Louis, MO26 студија
- Rochester, MN25 студија
- Columbus, OH25 студија
- Chicago, IL24 студија
- Milwaukee, WI23 студија
- Baldwin Park, CA23 студија
Ostale studije u gradu Durham
- Рак дојке63 студија
- Рак (све врсте)61 студија
- Немалоклетни карцином плућа42 студија
- Akutna mijeloidna leukemija34 студија
- Рак плућа33 студија
- Метастатски карцином33 студија
- Рак простате32 студија
- Колоректални карцином30 студија
- Рак јајника28 студија
- Hronična limfocitna leukemija28 студија
- Затајење срца25 студија
- Рак панкреаса24 студија
Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.